Clinical Trial

Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated August 1, 2022 (before its estimated October 25, 2023 completion). Its status may not reflect the trial's current state.
Summary
Indication:Patients with Advanced c-MET-positive Non-Small Cell Lung Cancer Phase Ib (China only): Approximately 90 patients Phase Ⅱ (globally): Approximately 78 evaluable patients; addition of at least 6 patients in Safety Run-in (US only)
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2020-02-12; most recent amendment 2024-12-27.
Status change: Recruiting → Completed 2024-10-14
Status change: Active, Not Recruiting → Recruiting 2022-07-28
Status change: Recruiting → Active, Not Recruiting 2022-04-13
Trial Details
NCT Number NCT04270591
Lead Sponsor Haihe Biopharma Co., Ltd.
Conditions C-Met Exon 14 Mutation
Enrollment 183 participants
Start Date 2019-07-15
Primary Completion 2023-10-25 (estimated)
Study Completion 2023-12-30 (estimated)
Updated on ClinicalTrials.gov 2022-08-01